<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080664</url>
  </required_header>
  <id_info>
    <org_study_id>27335</org_study_id>
    <nct_id>NCT01080664</nct_id>
  </id_info>
  <brief_title>A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies</brief_title>
  <official_title>A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EMD Serono decided to terminate enrollment based on a review of the available clinical data&#xD;
      and low probability of completing the trial based on the observed recruitment rate. Subjects&#xD;
      already enrolled in the study continued participation in the study, consistent with the&#xD;
      protocol, to study completion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this research study is to investigate for the first time the safety and&#xD;
      tolerability of a new drug (AS703569), called an aurora kinase inhibitor, being tested to&#xD;
      treat blood cancers in patients with different blood cancers. The research study will also&#xD;
      assess how the body breaks down AS703569 and what changes occur in the blood after oral doses&#xD;
      of AS703569. It will also look to see if there is any improvement in your blood cancer. The&#xD;
      use of AS703569 in this study is experimental.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Please see Purpose Statement below&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>21 days or 1 cycle</time_frame>
    <description>Dose-escalation part - The number of subjects experiencing at least a Dose-Limiting Toxicity (DLT), judged to be related to the study medication, evaluated over the first cycle only for each dose level and regimen, independently.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary anti-tumour activity</measure>
    <time_frame>42 days or 2 cycles</time_frame>
    <description>Cohort expansion part - Preliminary anti-tumour activity in four selected cohorts of haematological malignancies as assessed every two cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAE)</measure>
    <time_frame>minimum 21 days or 1 cycle</time_frame>
    <description>Dose-escalation and Cohort expansion parts The proportion/number of subjects experiencing treatment-emergent adverse events (TEAE) after the first cycle and during multiple cycles, in each cohort for each of the 2 dose-regimens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Haematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS703569</intervention_name>
    <description>Dose Escalation&#xD;
Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:&#xD;
Number of cycles: until progression or unacceptable toxicity develops.&#xD;
Cohort Expansion&#xD;
Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:&#xD;
Number of cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <other_name>Aurora kinase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS703569</intervention_name>
    <description>Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.&#xD;
Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Aurora kinase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Dose-escalation part:&#xD;
&#xD;
          -  Primary or secondary acute myeloid leukaemia, including subjects:&#xD;
&#xD;
        with first or subsequent relapse after standard therapy, with no established treatment&#xD;
        options; refractory to available therapies, e.g. who failed to achieve complete remission&#xD;
        after chemotherapies; Newly-diagnosed elderly subjects (over 60 years) according to WHO&#xD;
        classification (≥20 blasts in bone marrow), who did not accept or were not eligible for&#xD;
        chemotherapy (first line therapy)&#xD;
&#xD;
          -  Subjects with myelodysplastic syndrome (IPSS Int-2 or high risk) resistant or&#xD;
             intolerant to standard treatment and not candidates for allogeneic HSCT.&#xD;
&#xD;
          -  Subjects with chronic myeloid leukaemia in chronic, accelerated or blast-phase,&#xD;
             resistant or intolerant to standard treatment and not candidates for allogeneic HSCT.&#xD;
&#xD;
          -  Subjects with myeloproliferative disorders and no effective treatment options.&#xD;
&#xD;
          -  Subjects with acute lymphoblastic leukaemia, relapsing, resistant or intolerant to&#xD;
             standard treatment and no effective treatment options.&#xD;
&#xD;
          -  Subjects with chronic lymphocytic leukaemia, relapsing, resistant or intolerant to&#xD;
             standard treatment and no effective treatment options.&#xD;
&#xD;
          -  Subjects with non-Hodgkin lymphoma, relapsing, resistant or intolerant to standard&#xD;
             treatment with no effective treatment options.&#xD;
&#xD;
        Cohort expansion part&#xD;
&#xD;
          -  Primary or secondary acute myeloid leukaemia not eligible for chemotherapy (first line&#xD;
             therapy), including subjects&#xD;
&#xD;
        with first or subsequent relapse after standard therapy, for whom no established treatment&#xD;
        options are available; refractory to available therapies, e.g. who failed to achieve&#xD;
        complete remission after chemotherapies; Newly-diagnosed elderly subjects (over 60 years)&#xD;
        according to WHO classification (≥ 20 blasts in bone marrow), who did not accept or were&#xD;
        not eligible for chemotherapy (first line therapy)&#xD;
&#xD;
          -  Subjects with chronic myeloid leukaemia in chronic or accelerated phase, resistant or&#xD;
             intolerant to standard treatment, who have not achieved a complete haematological&#xD;
             response, and are not candidates for allogeneic HSCT.&#xD;
&#xD;
          -  Subjects with myeloproliferative disorders with no effective treatment options.&#xD;
&#xD;
          -  Subjects with Philadelphia chromosome positive acute leukaemias including acute&#xD;
             lymphoblastic leukaemia and blast phase chronic myeloid leukaemia, relapsing,&#xD;
             resistant or intolerant to standard treatment with no effective treatment options.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukaemia.&#xD;
&#xD;
          -  Ongoing uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.&#xD;
&#xD;
          -  Hyperleukocytosis with &gt;50x10(9)/L leukaemic blasts.&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, biologic therapy or any experimental anti-cancer therapy&#xD;
             within 28days prior to study Day1 and/or not having recovered from its toxicity.&#xD;
&#xD;
          -  Extensive radiotherapy involving ≥30% of bone marrow (e.g. whole pelvis, half spine)&#xD;
             within 6months prior to study Day1.&#xD;
&#xD;
          -  Active CNS disease involvement.&#xD;
&#xD;
          -  Any condition, including laboratory, medical history or pre-study assessment findings,&#xD;
             that in the opinion of the Investigator, constitute a risk or contraindication for&#xD;
             participation or that could interfere with the study objectives, conduct or evaluation&#xD;
             of a drug to be taken orally.&#xD;
&#xD;
          -  Clinically relevant cardiac abnormalities or clinically relevant abnormalities .&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus, active hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Signs and symptoms suggestive of transmissible spongiform encephalopathy.&#xD;
&#xD;
          -  Major surgery within 2weeks prior to study Day1.&#xD;
&#xD;
          -  Haemoglobin &lt;8g/dL at screening (can be transfused).&#xD;
&#xD;
          -  Refractory to platelet transfusion (defined as increase of &lt;20.109/L platelets 1hour&#xD;
             after transfusion).&#xD;
&#xD;
          -  Coexistent second malignancy or history of prior malignancy within previous 3years&#xD;
             (excluding basal or squamous cell carcinoma of the skin, and in situ carcinoma of the&#xD;
             cervix that has been treated curatively).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narmyn Rejeb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.A., Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTRC at the UT Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologie UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mont-Godinne University Hospital (UCL)</name>
      <address>
        <city>Yvoir</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universitat Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik</name>
      <address>
        <city>Ulm</city>
        <zip>D-89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitaux Universitaires</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen</name>
      <address>
        <city>St Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AS703569</keyword>
  <keyword>Aurora Kinase Inhibitor</keyword>
  <keyword>Haematological malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

